Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

Bullboard Posts

Post by kingposton Aug 04, 2015 2:23pm

105 Views

Post# 23987770

AVXL up 40% on 13 million volume

Since the cure for Alzheimers and other dimentia indications targeted (is such a huge market second only to Cancer in total market size) , IMO this stock has plenty of room yet to run..and likely more data within a couple monthes as their ongoing trial is "open adaptive" which makes issuing updates as things proceed possible... results this past July suggest it could be the cure to AD long awaited... I would consider it on a nice pull back...

Bullboard Posts

The top 10 Canadian medical stocks